Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. (Q53401747)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 October 2011

Language	Label	Description	Also known as
English	Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.	scientific article published on 20 October 2011

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

8

object named as

Jun Hyuk Hong

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

9

object named as

Choung-Soo Kim

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

10

object named as

Hanjong Ahn

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

7

object named as

Cheryn Song

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

Jae-Lyun Lee

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Jin-Hee Ahn

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Se Hoon Park

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Ho Young Lim

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Shin Ahn

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

publication date

20 October 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Investigational New Drugs

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

30

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1984-1990

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

https://scigraph.springernature.com/pub.10.1007/s10637-011-9757-7

0 references

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Progress in the chemotherapy of metastatic cancer of the urinary tract

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Prophylaxis for paclitaxel hypersensitivity reactions

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Phthalate Esters and Their Effect on the Liver

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micelles.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9757-7

21 January 2018

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/22012004

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paclitaxel in the treatment of advanced urothelial cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22012004

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22012004

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22012004

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/22012004

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22012004

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers

1 reference

https://pubmed.ncbi.nlm.nih.gov/22012004

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22012004

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-011-9757-7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22012004%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53401747&oldid=2087119244"